Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine
Overview
- Phase
- Phase 2
- Intervention
- Placebo
- Conditions
- Acute Migraine
- Sponsor
- Zosano Pharma Corporation
- Enrollment
- 365
- Locations
- 36
- Primary Endpoint
- Proportion of Subjects With Freedom From Most Bothersome Pre-specified Other Symptom (Nausea, Photophobia, or Phonophobia Pre-specified by Subject)
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
This is a randomized, double-blind, multi-center, parallel-group study designed to compare the safety and efficacy of a range of doses of ZP-Zolmitriptan intracutaneous microneedle systems to placebo.
Detailed Description
This is a randomized, double-blind, multi-center, parallel group study designed to compare the safety and efficacy of a range of doses of ZP-Zolmitriptan intracutaneous microneedle systems to placebo. Subjects who have consented and meet the entry criteria will be randomized to one of four blinded treatment groups. There will be a screening period of up to 1 week, followed by a run-in period to record migraine activity. The run-in period is to determine eligibility for randomization, and is planned to be 4 weeks in duration but may be extended up to an additional 4 weeks to accommodate scheduling. Qualified subjects will randomize to the double-blind treatment period at Day 0 and will have up to 8 weeks to confirm and treat a qualifying migraine. Using the eDiary to confirm they are experiencing a qualified migraine, subjects will self-administer the patch or patches and continue to respond to questions in the eDiary for 48 hours post treatment administration.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Greater than 1 year history of episodic, acute migraine (with or without aura) with onset prior to 50 years of age. Diagnosis must comply with International Headache Society (IHS) diagnostic criteria. Diagnostic criteria must include a history of at least five attacks not attributed to any other disorder that include all of the following criteria:
- •Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)
- •Headache has at least two of the following characteristics:
- •(i) unilateral location (ii) pulsating quality (iii) moderate or severe pain intensity (iv) aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) c) During headache at least one of the following: (i) nausea and/or vomiting (ii) both photophobia and phonophobia
- •Migraine history during the 6-month period prior to the run-in period must include: 2-8 migraines per month and no more than 10 headache days per month
- •Women of child-bearing potential must not be pregnant, must agree to avoid pregnancy during the trial, and must use an acceptable methods of birth control for the duration of the trial.
- •No significant ECG findings, defined by:
- •ischemic changes
- •Q-waves in at least two contiguous leads,
- •clinically significant intra-ventricular conduction abnormalities (left bundle branch block or Wolf-Parkinson-White syndrome), or
Exclusion Criteria
- •Contraindication to triptans
- •Use of any prohibited concomitant medications within 10 days of the Run-in Period
- •History of hemiplegic or basilar migraine
- •Participation in another investigational trial during the 30 days prior to the Run-in Period or during this study
- •Previous participation in a clinical trial of ZP-Zolmitriptan
- •Diagnosis of cancer (other than non-invasive skin cancer) within the 5 years prior to the Run-in Period
- •History of unstable psychiatric illness requiring medication or hospitalization in the 12 months prior to the Run-in Period
- •Subjects who have known allergy or sensitivity to zolmitriptan or its derivatives or formulations
- •Subjects who have known allergy or sensitivity to adhesives
- •Planned participation in activities which cause inflammation, irritation, sunburn, lesions, or tattoos at the intended application site from two weeks prior to screening through the last day of study participation
Arms & Interventions
Placebo
Placebo (either single or double patch) single administration
Intervention: Placebo
ZP-Zolmitriptan 3.8 mg
ZP-Zolmitriptan 3.8 mg (1.9 mg x 2 patches) single administration
Intervention: ZP-Zolmitriptan
ZP-Zolmitriptan 1 mg
ZP-Zolmitriptan 1 mg patch single administration
Intervention: ZP-Zolmitriptan
ZP-Zolmitriptan 1.9 mg
ZP-Zolmitriptan 1.9 mg patch single administration
Intervention: ZP-Zolmitriptan
Outcomes
Primary Outcomes
Proportion of Subjects With Freedom From Most Bothersome Pre-specified Other Symptom (Nausea, Photophobia, or Phonophobia Pre-specified by Subject)
Time Frame: 2 hours
The proportion of subjects with freedom from the subject's pre-specified most bothersome symptom at 2 hours is one of two parts of the co-primary efficacy endpoint. This endpoint will be evaluated separately but both endpoints have to be met statistically for the study to be considered a success.
Proportion of Subjects With Pain Freedom
Time Frame: 2 hours
Pain Freedom at 2 hours post study drug administration is one of the co-primary endpoints. Subjects were queried via their eDiary about their level of migraine pain (none, mild, moderate, or severe) at various intervals post-dose. Subjects who answered none at 2 hours post study drug were considered pain free at 2 hours.